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We describe a death associated with multidrug-
resistant tuberculosis and HIV infection outside Africa that 
can be linked to Tugela Ferry (KwaZulu-Natal, South Africa), 
the town most closely associated with the regional epidemic 
of drug-resistant tuberculosis. This case underscores the 
international relevance of this regional epidemic, particularly 
among health care workers.
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) pose an increasing 
challenge to international health (1), particularly in the 
context of HIV infection. An outbreak of XDR TB around 
a rural hospital in Tugela Ferry (KwaZulu-Natal Province, 
South Africa) in 2006 received widespread international 
attention, in part because of the high case-fatality rate. 
More recent work has highlighted the risk for MDR TB 
among health care workers (2) in South Africa. We report 
a death outside of Africa associated with MDR TB that 
can be directly related to the epidemic of drug resistance 
in Tugela Ferry, the center most closely associated with the 
epidemic.
The Study
A 42-year-old South Africa–born health care worker 
was admitted to a regional hospital in the United Kingdom 
with a 1-month history of fever, cough, and weight loss 
associated with cervical lymphadenopathy, choroidal 
tuberculoma (Figure), and pleural effusion. The patient 
had no history of TB treatment and no known family 
contact with TB. He had moved to the United Kingdom 
6 years earlier. Extrapulmonary TB diagnosis was based 
on microscopic examination of a cervical lymph node 
specimen, and co-infection with HIV was identifi ed (CD4 
count 5 cells/μL).
After arrival in the United Kingdom, the patient worked 
as a temporary nurse in several health care facilities. Before 
that, the patient worked at the Church of Scotland Hospital 
in Tugela Ferry during 1996–2002 in general medical 
wards. This facility was the focus of the 2006 report of 
XDR TB, and most MDR isolates identifi ed there during 
2005–2007 were XDR TB (3).
A presumptive diagnosis of MDR TB was made 7 
days after the patient sought care at the hospital. A line 
probe assay (INNO-LiPA Rif.TB; Innogenetics, Ghent, 
Belgium) performed on cervical lymph node aspirates 
identifi ed Mycobacterium tuberculosis and a hybridization 
pattern consistent with rpoB gene mutation (associated 
with rifampin resistance and a high risk for MDR TB). 
Treatment was altered from weight-appropriate doses 
of rifampin, isoniazid, pyrazinamide, and ethambutol 
to include levofl oxacin, amikacin, cycloserine, and 
protionamide. Because of known sensitivity patterns 
from isolates at Tugela Ferry and the possibility of XDR 
TB, para-aminosalicylic acid and linezolid were added 
to treatment, and intravenous amikacin was changed to 
capreomycin. Treatment was subsequently changed on 
the basis of culture results. The patient required 35 days 
of mechanical ventilation for likely pulmonary immune 
reconstitution syndrome after initiation of antiretroviral 
treatment. Although discharged from intensive care 
after successful treatment of TB, the patient remained 
hospitalized and died 90 days after fi rst seeking care. 
Samples cultured from >1 site showed evidence of 
widespread MDR TB. More than 500 potentially infectious 
contacts were identifi ed, but no secondary cases of TB 
have been diagnosed.
Culture confi rmed the M. tuberculosis isolate from the 
patient to be resistant to rifampin, isoniazid, pyrazinamide, 
and ethambutol but sensitive to amikacin, capreomycin, 
moxifl oxacin, para-aminosalicylic acid, and linezolid. 
These resistance and sensitivity characteristics identifi ed 
the isolate as MDR TB rather than an XDR TB strain. 
Automated sequencing of rpoB revealed the L533P mutation 
previously associated with rifampin resistance (4–6) but not 
the D516G mutation found in XDR TB strains previously 
isolated from patients at Church of Scotland Hospital and 
from other hospitals within KwaZulu-Natal (7).
To explore whether the patient’s isolate was related 
to the F15/LAM4/KZN strain genotypes associated with 
the Tugela Ferry outbreak (8) and the broader population 
of drug-resistant strains in the region, we performed 
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mycobacterial interspersed repetitive units (MIRU)–
variable number tandem repeats (VNTR) typing and 
spoligotyping (9). The isolate displayed a typical LAM4 
spoligotype (111111111111111111110000111111110000
1110111), consistent with a F15/LAM4/KZN genotype. In 
the absence of full MIRU-VNTR typing for Tugela Ferry 
strains, the alleles of 15 loci were compared with those 
inferred by in silico analysis of publicly available genome 
sequences for fi ve F15/LAM4/KZN strains from Tugela 
Ferry or KwaZulu-Natal (7,10). The patient’s isolate 
differed by only a single locus from the F15/LAM4/KZN 
605 reference strain, whereas the 4 other strains of this 
genotypic family varied by 1 to 3 loci (Table). Single-locus 
variation is prognostic of a close relationship within a clonal 
complex with confi dence exceeding 99% (9). Furthermore, 
the patient’s isolate genotype also specifi cally best matched 
that of an F15 strain (also differing by 1 locus), in a database 
of 209 South African isolates containing a large variety of 
genotypic families (11).
Conclusions
The risk for TB among health care workers in 
developing countries is well recognized (12) but has 
become more of a public health concern with evidence of 
the nosocomial transmission of MDR and XDR TB in South 
Africa. Nosocomial transmission of drug-resistant TB has 
been reported from well-resourced settings (13), but this 
case highlights how migration of health care workers can 
link the 2 settings.
When taken together, the clinical and molecular 
epidemiologic data in this case support the hypothesis that 
infection was acquired in South Africa and most likely 
while the patient was based in Tugela Ferry. Health care 
workers in South Africa are signifi cantly more likely to 
be admitted to a hospital with MDR or XDR TB than are 
population controls (2), and this patient had prolonged 
occupational exposure at a hospital strongly associated with 
drug-resistant TB. Although F15/LAM4/KZN strains are 
frequent in South Africa, MDR versions of this genotype 
emerged in the KwaZulu-Natal Province in the mid-1990s, 
at the same time that the prevalence of HIV was increasing 
to hyperendemic levels and before antiretroviral therapy 
was widely available (8). The fact that this patient’s isolate 
and the XDR strains from Tugela Ferry have different rpoB 
mutations suggests that these strains arose independently 
from the locally circulating F15/LAM4/KZN strain pool, 
as already suggested for other MDR F15/LAM4/KZN 
strains (7).
Since this patient left South Africa, multidrug 
resistance has continued to grow as a challenge to public 
health, fueled in part by the HIV epidemic (14) and despite 
greater availability of HIV treatment. Given the long latent 
period between infection and the time when patients seek 
care for symptoms, it is reasonable to expect that such cases 
may become increasingly common outside Africa. If they 
do become more common, this change has implications 
for diagnostics, clinical management, and public health 
policy. In settings where prevalence is low but availability 
of resources is high, such as Europe and the United States, 
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Figure. Retinal image from patient with evidence of choroidal 
tuberculosis.
Table. Locus typing for tuberculosis patient isolate according to standard nomenclature based on chromosomal locations* 
Genotypic family and 
strain or isolate
Allele at MIRU-VNTR locus
154 577 580 802 960 1644 2059 2165 2461 2531 2687 2996 3007 3192 4348
F15/LAM4/KZN 
 Patient isolate 1 4 3 4 4 3 2 2 2 6 1 5 3 3 2
 605 (reference) 1 4 2 4 4 3 2 2 2 6 1 5 3 3 2
 1435 1 4 2 5 4 3 2 2 2 6 1 5 3 3 2
 R506 1 4 2 3 3 3 2 2 2 6 1 4 3 3 2
 V2475 1 4 2 3 3 3 2 2 2 6 1 4 3 3 2
 4207 1 4 2 3+4 3+4 3 2 2 2 6 1 4+5 3 3 2
F11/LAM 
 F11 2 4 2 3 3 3 2 2 2 6 1 4 3 3 2
*Patient’s isolate most closely matches F15/LAM4/KZN605 reference strain by a single locus variation, a genetic distance equal to or lower than that 
separating other known F15/LAM4/KZN strains (i.e., 1–3 locus variations). MIRU-VNTR, mycobacterial interspersed repetitive units–variable number 
tandem repeats. 
MDR TB from South Africa
access to molecular diagnostic testing remains variable 
despite recent advances (15). The INNO-LiPA Rif.TB assay 
used here provided useful information with an indication 
of potential multidrug resistance. However, despite early 
molecular testing, identifi cation of MDR or XDR TB still 
depended on conventional methods of susceptibility testing. 
Potentially toxic medications could have been avoided if 
more extensive molecular testing for resistance to second-
line drugs (particularly quinolones and aminoglycosides) 
were achievable in close physical proximity to the patient.
The poor outcome for MDR and XDR TB in HIV-
positive patients is well recognized in disease-endemic 
settings (3), and this case confi rms the high risk for death 
even in well-resourced settings. This case also highlights 
defi ciencies in screening policies at national borders and 
within occupational health, particularly for health care 
workers not in permanent employment. Barriers to HIV and 
TB testing are multifactorial, and TB screening methods 
have limitations; nonetheless, in this situation, there were 
several missed opportunities for diagnosis of TB and HIV 
that could have prevented this patient’s death.
This report serves as a reminder that XDR or MDR TB 
and HIV in sub-Saharan Africa represent not just a regional 
epidemic but also a challenge to international health. 
Although this challenge has yet to fully emerge, this case 
highlights the potential risk to health care workers in areas 
of low and high transmission.
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